Current industry best practices and FDA guidelines urge therapeutic antibody developers to use affinity-purified polyclonal antibodies in anti-drug assays for immunogenicity studies as well as controls for ongoing drug monitoring.
MBS delivers sensitive and specific positive ADA controls through:
- Dedicated project management of polyclonal antibody development
- Goal-driven immunization strategies
- Advanced, application-specific screening of serum samples
- Custom affinity purification
- Lifetime supply of antibody generated within 5 months
[Attachment]
Maine Biotechnology Services Inc. published this content on 31 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 January 2017 04:44:03 UTC.
Original documenthttp://mainebiotechnology.com/anti-drug-antibody-reagent-development/
Public permalinkhttp://www.publicnow.com/view/A0B4337465F0DFD237E356B43AC28449D340012C
